179899-03-7

Basic information

• Product Name: 3-Ethyl-2,2-diMethyl-1,2,3,4-tetrahydroquinoline
• Synonyms: 3-Ethyl-2,2-diMethyl-1,2,3,4-tetrahydroquinoline
• CAS NO: 179899-03-7
• Molecular Formula: C13H19N
• Molecular Weight: 189.29666
• Mol File: 179899-03-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Ethyl-2,2-diMethyl-1,2,3,4-tetrahydroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethyl-2,2-diMethyl-1,2,3,4-tetrahydroquinoline(179899-03-7)
• EPA Substance Registry System: 3-Ethyl-2,2-diMethyl-1,2,3,4-tetrahydroquinoline(179899-03-7)

Safety Data

• Hazardous Substances Data: 179899-03-7(Hazardous Substances Data)

Upstream product

• 75-03-6 ethyl iodide 
• 179898-87-4 1-tert-butoxycarbonyl-1,2,3,4-tetrahydro-2,2-dimethyl-4-quinolinone 
• 14465-61-3 2,2-dimethyl-1,2-dihydroquinoline 
• 7471-09-2 3-methyl-3-phenylamino-1-butyne 
• 179898-89-6 1-tert-butoxycarbonyl-1,2-dihydro-2,2-dimethylquinoline 
• 300808-64-4 4-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 59-31-4 2-quinolone 

Relevant articles and documents

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines

A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR- mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure - activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

Steroid receptor modulator compounds and methods

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiting steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.